NCT07486934Phase 3Recruiting

Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Study sponsor: Dyne Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-07Estimated
Enrollment · participants150Estimated
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source